INDIANA YUNIVERSITI RISERCH END TEKNOLODZHI KORPOREJSHN
发明人:
ERIKSON Krejg A. (US),ЭРИКСОН Крейг А. (US),LAKHIRI Debomoj K. (US),ЛАХИРИ Дебомой К. (US)
申请号：
RU2015105947
公开号：
RU0002675252C2
申请日:
2013.07.22
申请国别(地区):
RU
年份:
2018
代理人:
摘要：
FIELD: medicine.SUBSTANCE: group of inventions relates to the modulation of serum protein levels for the treatment of patients with fragile X chromosome syndrome (FXS) and autism spectrum disorders (ASD). Disclosed is a method of treating ASD or FXS in a patient, comprising steps of: contacting a first plasma sample from a patient diagnosed with ASD or FXS with reagents that selectively bind to brain-derived neurotrophic factor (BDNF), secreted amyloid precursor protein (sAPP), secreted amyloid alpha precursor protein (sAPPα)； determining BDNF, sAPP and sAPPα levels in said plasma sample； administering acamprosate or a pharmaceutically acceptable salt thereof to a patient； binding a second plasma sample from said patient with reagents that selectively bind to BDNF, sAPP, sAPPα； determining if there is a change in the levels of BDNF, sAPP and sAPPα in the plasma of said patient； adjusting the amount of acamprosate or a pharmaceutically acceptable salt thereof administered to said patient in response to a change in the levels of BDNF, sAPP and sAPPα, determined in the plasma samples of said patient. Also disclosed is the use of a system for monitoring the treatment of ASD and FXS, a method of screening for a compound for the treatment of ASD and FXS, and a method for treating ASD or FXS in a patient, including administering acamprosate and monitoring the patient's peripheral blood.EFFECT: group of inventions provides effective monitoring of the treatment of ASD and FXS.16 cl, 2 dwg, 8 tblГруппа изобретений относится к модуляции уровней белков сыворотки для лечения пациентов с синдромом хрупкой X-хромосомы (FXS) и нарушениями аутистического спектра (ASD). Раскрыт способ лечения ASD или FXS у пациента, предусматривающий стадии: контактирования первого образца плазмы от пациента с диагнозом ASD или FXS с реагентами, которые селективно связываются с полученным из головного мозга нейротрофическим фактором (BDNF), секретируемым белком-предшественником амилоида (sAPP), секре
